ilaprazole + levofloxacin + amoxicillin

This is a **combination therapy** consisting of three drugs: ilaprazole (a proton pump inhibitor), levofloxacin (a fluoroquinolone antibiotic), and amoxicillin (a beta-lactam antibiotic). The regimen has been primarily studied as a **triple therapy for the eradication of Helicobacter pylori infection** in patients with gastric ulcer, duodenal ulcer, or gastritis. - **Ilaprazole** suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase proton pump in gastric parietal cells, increasing intragastric pH and making H. pylori more sensitive to antibiotics. - **Levofloxacin** inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription in susceptible organisms. - **Amoxicillin** inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, resulting in cell lysis. The combination is especially considered in regions with high antibiotic resistance or when traditional clarithromycin-based triple therapy is suboptimal. Clinical trials have found a 10-day regimen (ilaprazole 10 mg bid, levofloxacin 500 mg bid, amoxicillin 1000 mg bid) yields high eradication rates (88.8% per protocol), with a favorable safety profile and few adverse effects[2].